Expand all sections

Botulinum A toxin

Dysport

Extended indication Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI).
Therapeutic value Possible equal value
Total cost 2,754,000,000.00

Product

Active substance Botulinum A toxin
Domain Neurological disorders
Main indication Muscular diseases
Extended indication Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI).
Proprietary name Dysport
Manufacturer Ipsen
Route of administration Intramuscular
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Orphan drug No

Therapeutic value

Current treatment options Botox, Fenol, Baclofen intrathecaal, Dantroleen, tizanidine, diazepam, clonidine, cannabis.
Therapeutic value Possible equal value
Substantiation Mogelijke gelijke waarde verwacht aan Xeomin.
Duration of treatment continuous
Dosage per administration Totaal 1000 tot 1500 units per cyclus
References https://www.ipsen.com/websites/IPSENCOM-PROD/wp-content/uploads/2017/06/16182401/16-06-2017-sNDA-DYSPORT-ALL-US-FINAL-1.pdf, clinicaltrials.gov: NCT01249404, NCT01251367,
Additional remarks Toedieningsfrequentie: indien nodig elke 12-16 week herhalen.

Expected patient volume per year

Patient volume

< 1,020,000

Market share is generally not included unless otherwise stated.
References Martin A. et al. Neuropsychiatr Dis Treat. 2014 Jan 23;10:111-22. doi: 10.2147/NDT.S53913.
Additional remarks LLS post stroke: 40-600 per 100.000 (68.000-1.020.000 in NL), LLS post TBI: 100-235 per 100.000 (17.000-399.500 in NL)

Expected cost per patient per year

Cost 2,400.00 - 3,000.00
References Medicijnkosten.nl
Additional remarks Huidige VVP 500 eenheden dysport circa 200 – 250 euro. Per behandeling 1500 eenheden dus 600 – 750 euro. 4 behandelingen per jaar = 2400 - 3000 euro. Meerkosten t.o.v. orale therapie / gelijke kosten t.o.v. overige botox preparaten.

Potential total cost per year

Total cost

2,754,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use Yes
Indications off label use In de praktijk zal het mogelijk off label worden gebruikt omdat een ziekenhuis doorgaans niet alle botuline preparaten op voorraad heeft.

Indication extension

Indication extension No

Other information

There is currently no futher information available.